TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23514036
Drug: Heme Iron
Normalized name: HEME IRON
DrugBank: Ferroheme (DB18267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme Iron Polypeptide (HIP) 11 mg orally 3 times per day
Study: 23514036
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose 200 mg monthly for 6 months
Study: 6436182
Drug: Cefroxadine 250
Normalized name: cefroxadine
DrugBank: Cefroxadine (DB11367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefroxadine 250 mg q.i.d. for ten days
Study: 6436182
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg q.i.d. for ten days
Study: 31469303
Drug: Lixisenatide combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide combined with basal insulin
Study: 29271022
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation (120 mg elemental iron, 3 mg folic acid, 100 mg vitamin C)
Study: 29271022
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation (60 mg elemental iron, 1 mg folic acid, 100 mg vitamin C)
Study: 18827074
Drug: XP13512 immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily)
Study: 18827074
Drug: XP13512 extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP13512 extended-release (equimolar dose compared with 600 mg gabapentin)
Study: 18827074
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin (up to 1200 mg)
Study: 16114985
Drug: Patient-specific vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific vaccine (3 weekly injections of irradiated tumor cells)
Study: 6139119
Drug: Diazepam 27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 27 mg
Study: 30545596
Drug: Swallowable gas-filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowable gas-filled intragastric balloon system plus lifestyle therapy
Study: 30545596
Drug: Lifestyle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle therapy alone
Study: 26821696
Drug: Epinephrine 0.05
Normalized name: EPINEPHrine 0.05 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 0.05 µg kg(‐1) min(‐1) infusion
Study: 24613294
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (6 soft-gel capsules of fish oil daily for 4 months)
Study: 24613294
Drug: Placebo (paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (paraffin oil capsules)
Study: 22273457
Drug: Intracoronary bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus and continuous intravenous infusion of eptifibatide (Group B, n=88)
Study: 19798503
Drug: PGB-monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB-monotherapy
Study: 19798503
Drug: Non-PGB drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PGB drugs
Study: 15669555
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (HRT) with 2 mg estradiol valerate and 2 mg dienogest
Study: 12499617
Drug: Nicorandil cocktail
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil cocktail (24 mg nicorandil, 5 mg nitroglycerin, 10,000 U heparin)
Study: 12499617
Drug: Verapamil cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil cocktail (10 mg verapamil, 5 mg nitroglycerin, 10,000 U heparin)
Study: 1479795
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tyrosine per kg body weight per day
Study: 30291682
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of cytidine (2%, 3%, and 4% w/w)
Study: 30291682
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control formulation
Study: 29609720
Drug: Saline bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline bolus of 22 mL/kg body weight
Study: 29609720
Drug: Minimum rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minimum rate saline infusion (control)
Study: 19747047
Drug: ICP-targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-targeted therapy based on the Lund concept
Study: 15694110
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 microg/24 h (Femseven)
Study: 12400528
Drug: Tetravalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent meningococcal polysaccharide vaccine conjugated to diphtheria at 1, 4, and 10 microg/ml dosages
Study: 12400528
Drug: Tetravalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent meningococcal polysaccharide vaccine conjugated to diphtheria at 4 microg/ml
Study: 31488289
Drug: T+S (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+S (0.5 mg testosterone and 50 mg sildenafil) under fed conditions
Study: 31488289
Drug: T+S (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+S (0.5 mg testosterone and 50 mg sildenafil) under fasted conditions
Study: 19419443
Drug: Adjunctive intra-muscular
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive intra-muscular neridronate (12.5 mg injection/week for 3 months)
Study: 19419443
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment (PT) only
Study: 16393441
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (0.2 mg)
Study: 16393441
Drug: Desloratadine tablets
Normalized name: Desloratadine Tablets
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine tablets (5 mg)
Study: 9215017
Drug: Hyaluronidase 300
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase 300 iu ml‐1
Study: 9215017
Drug: Hyaluronidase 50
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase 50 iu ml‐1
Study: 7535064
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (high-dose, low-dose, placebo)
Study: 7535064
Drug: Aprotinin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (high and low doses)
Study: 3555584
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg + HCTZ 12.5 mg (25/12.5)
Study: 3555584
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + HCTZ 25 mg (50/25)
Study: 3555584
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg + HCTZ 50 mg (100/50)
Study: 26480205
Drug: Telephone-administered psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered psychotherapy (T-P)
Study: 26480205
Drug: Telephone-administered social
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered social rhythm therapy (T-SRT)
Study: 26480205
Drug: Telephone-administered intensive
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered intensive clinical management (T-ICM)
Study: 9892124
Drug: Modified flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified flexible suture implant
Study: 31866929
Drug: eCBT‐I (automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: eCBT‐I (automated Internet‐delivered cognitive behavioral therapy for insomnia)
Study: 31866929
Drug: mPT (minimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: mPT (minimal psychoeducation therapy)
Study: 26638161
Drug: SoluMatrix meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoluMatrix meloxicam 10 mg (fasting)
Study: 26638161
Drug: meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 15 mg tablets (fasting)
Study: 26638161
Drug: SoluMatrix meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoluMatrix meloxicam 5 mg (fasting)
Study: 26638161
Drug: SoluMatrix meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoluMatrix meloxicam 10 mg
Study: 22803939
Drug: Person‐Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person‐Based Cognitive Therapy (PBCT) plus Treatment as Usual (TAU)
Study: 20934698
Drug: Double-bundle ACL
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-bundle ACL reconstruction technique (ST/G)
Study: 17637192
Drug: Fast release
Normalized name: Delsym Cough Maximum Strength Fast Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast release formulation
Study: 17637192
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release formulation
Study: 12180532
Drug: AERx pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERx pulmonary delivery system with ABT-431 (1, 2, 4, and 8 mg doses)
Study: 12180532
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ABT-431 (5 mg over 1 hr)
Study: 10343980
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (2 mg every 4 hours until delivery)
Study: 1944468
Drug: Prolonged administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged administration of epipodophyllotoxin (teniposide with or without etoposide) twice weekly or weekly
Study: 1944468
Drug: Epipodophyllotoxins administered
Normalized name: Epidophyllotoxin
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epipodophyllotoxins administered twice weekly
Study: 1944468
Drug: Epipodophyllotoxins administered
Normalized name: Epidophyllotoxin
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epipodophyllotoxins administered weekly
Study: 1944468
Drug: No epipodophyllotoxins
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epipodophyllotoxins or treated only during remission induction or every two weeks during continuation treatment
Study: 6750780
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg penicillamine daily
Study: 6750780
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg penicillamine daily
Study: 28536868
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg‐1 body mass)
Study: 9297732
Drug: Vancomycin intravenous
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin intravenous loading dosage
Study: 3535661
Drug: Piperacillin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (18 g/day)
Study: 3535661
Drug: Cefoxitin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (12 g/day)
Study: 29802852
Drug: Curcumin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1,500 mg orally, twice per day)
Study: 27487408
Drug: Live educational
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live educational music therapy
Study: 27487408
Drug: Recorded educational
Normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recorded educational music therapy
Study: 25831695
Drug: Combined anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anesthesia (CA) with thoracic epidural analgesia using ropivacaine 0.3%, fentanyl 4 µg/ml, and epinephrine 2 µg/ml, followed by epidural infusion of ropivacaine 0.2%, fentanyl 2 µg/ml, and epinephrine 2 µg/ml for 5-7 days post-surgery.
Study: 23425955
Drug: T40/A5 FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: T40/A5 FDC therapy (telmisartan 40 mg + amlodipine 5 mg)
Study: 10638607
Drug: Combined radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiation therapy (RT) and chemotherapy (50 Gy in 25 fractions over 5 weeks, plus cisplatin 75 mg/m2 i.v. on specific weeks, and continuous infusion fluorouracil (5FU) 1 g/m2 per day for the first 4 days of the same weeks)
Study: 10638607
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) alone (64 Gy in 32 fractions over 6.4 weeks)
Study: 10638607
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy plus esophagectomy (three cycles of preoperative cisplatin and 5FU, two cycles after operation for responding patients)
Study: 10638607
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and 5FU)
Study: 1736753
Drug: Clonidine 0.2
Normalized name: CLONIDINE 0.2MG/24HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2 mg orally at bedtime
Study: 31371144
Drug: VRRS‐Tablet (experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRRS‐Tablet (experimental linguistic treatment)
Study: 31371144
Drug: Traditional linguistic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional linguistic treatment (control)
Study: 24699894
Drug: Sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric oxyhydroxide 1 g
Study: 22967202
Drug: Internet-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-help problem solving treatment (PST)
Study: 10834665
Drug: Serum SLPI
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum SLPI in septic surgical patients (132+/‐15 ng/mL)
Study: 10834665
Drug: Serum SLPI
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum SLPI in healthy adults after lipopolysaccharide administration (50.2+/‐4.0 ng/mL)
Study: 1635361
Drug: Prostacyclin (Epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin (Epoprostenol Wellcome or Chinoin) at a dose of 5 mg/kg/min intravenously in 5 infusions
Study: 10922161
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthwash (used twice daily)
Study: 29664853
Drug: FX006 (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX006 (32 mg)
Study: 29664853
Drug: Saline‐solution placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline‐solution placebo
Study: 27235297
Drug: Provider and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider and patient/caregiver focused intervention including operational guidelines, systematic training, peer review of antibiotic prescribing, health education to patient caregivers, printed educational materials, and educational videos.
Study: 25496487
Drug: l-carnitine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine (12 g)
Study: 23583604
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg per day (including a 2 week run in of 100 mg per day) plus active supportive care
Study: 23583604
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg per day
Study: 16373466
Drug: Interactive CD-ROM
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive CD-ROM program on safe medication practices
Study: 12450908
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (1 dose of 60 mg Fe/d)
Study: 12450908
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (2 doses of 60 mg Fe once weekly)
Study: 10510150
Drug: Placebo antitussive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo antitussive preceded at 1 h by placebo inhibitor
Study: 10510150
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral DEX preceded at 1 h by placebo inhibitor (DEX30)
Study: 10510150
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral DEX preceded at 1 h by placebo inhibitor (DEX60)
Study: 10510150
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral DEX preceded at 1 h by 50 mg oral quinidine sulphate (QDEX30)
Study: 8834127
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (prednisone 10-15 mg/day) plus supplementary home oxygen therapy (mean 16.4 h/day) for 4 years.
Study: 8834127
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (prednisone 10-15 mg/day) without home oxygen therapy for 4 years.
Study: 2036669
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and Metoprolol (higher doses)
Study: 7016223
Drug: Alkeran (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkeran (600 mg/m2 x 5 days every 6 weeks)
Study: 29259196
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without inhaled nitrous oxide)
Study: 27069173
Drug: Pre-hydration with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hydration with 15 mEq magnesium sulfate (Mg-hydration group)
Study: 27069173
Drug: Non-pre-hydration (non-Mg-hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pre-hydration (non-Mg-hydration group)
Study: 19248130
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with infliximab
Study: 19248130
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with prednisone
Study: 17884605
Drug: Self-administered SCREEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered SCREEN II
Study: 17884605
Drug: Telephone-administered SCREEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered SCREEN II
Study: 11741732
Drug: Phosphoric acid
Normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphoric acid gel for 60s
Study: 7798679
Drug: Towne vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Towne vaccine (approximately 500 pfu)
Study: 7798679
Drug: Towne vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Towne vaccine
Study: 11527124
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Study: 11527124
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Study: 25471197
Drug: Caffeine (expected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (expected and administered)
Study: 23429905
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (300 mL)
Study: 22013793
Drug: Xinluotong Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinluotong Tablet (XLTT), four tablets each time, three times a day
Study: 22013793
Drug: Yangxinshi Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxinshi Tablet (YXST), three tablets each time, three times a day
Study: 22013793
Drug: Xinluotong Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinluotong Tablet (XLTT)
Study: 22013793
Drug: Yangxinshi Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxinshi Tablet (YXST)
Study: 17938390
Drug: Aspirin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 100 mg
Study: 14607578
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (leuprolide acetate; 1 mg/d, SC)
Study: 14607578
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA; 20 mg/d)
Study: 29896798
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion to achieve target MAP of 75 mm Hg
Study: 29896798
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion to achieve target MAP of 90 mm Hg
Study: 29896798
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion to achieve target MAP of 60 mm Hg
Study: 25730591
Drug: Dance Movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance Movement Therapy (DMT) during radiotherapy (6 sessions at 90 minutes each)
Study: 25730591
Drug: Dance Movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance Movement Therapy (DMT) after radiotherapy (1 to 2 months post-treatment)
Study: 24668261
Drug: Harp therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harp therapy during embryo transfer
Study: 24668261
Drug: Harp therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harp therapy